Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q4 2014 · 10-K
Revenue$147.98M$147.98M+50.8% vs Q4 2013 Net Income$30.12M$30.12M+97.8% vs Q4 2013 EPS Diluted$0.66$0.66+61.0% vs Q4 2013 Operating Income$44,620,000+91.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$35,769,000+3,339.3% Margins · derivedOperating margin30.2%+6.4 pt vs Q4 2013
Net margin20.4%+4.8 pt vs Q4 2013
ended Dec 31, 2014 · filed Mar 6, 2015 · 65 d after period end